Aluna's AI-enabled respiratory management platform allows patients to transmit data to their doctor by blowing into their innovative spirometer daily.
The patient-facing app gives patients an easy way to collect symptoms, medication, activity, and environmental factors.
Their proprietary ML algorithms help medical teams identify respiratory problems and take corrective action to keep their health under control.
Roughly one in thirteen Americans has asthma, and the number is rising due to environmental factors, according to the Asthma and Allergy Foundation of America.
Asthma attacks lead to over 1m emergency room visits each year, according to the American College of Asthma, Allergy & Immunology.
Aluna's FDA-cleared spirometer device and easy-to-use app encourage patients to easily share their lung health with their doctor while on-the-go.
This allows allergists, pulmonologists and other providers to offer care early and avoid costly and frightening hospital visits for the patient.
Aluna is eligible for insurance coverage under Remote Patient Monitoring.
Led by previous investor Matrix Partners, the series B round brings Aluna's total funding since inception to USD 27m.
Key investors in the round also include New York-based Rho Ignition, and Dr. Warner Carr, an Irvine, California-based allergist whose practice is an early adopter of Aluna's platform.
The series B funding comes on the heels of a year of rapid growth, with Aluna adding thousands of new patients to its platform for a year-over-year growth rate of 10x.
The company plans to invest both on the product and commercial side to produce more spirometers, make its offering more robust and reach new patients.
Aluna has recently added a Silicon Valley veteran to its executive team to focus on finance as the company scales.
Alex Gurevich joins Aluna as chief financial officer, bringing decades of finance and operations experience at high-growth companies including Credit Karma, Zendesk and Google.
Most recently, Alex was chief operating officer at Octane AI, a marketing and data platform for ecommerce merchants.
Created by co-founders Charvi Shetty and Inderjit Jutla, Aluna began as a project for UC Berkeley's bioengineering program.
Jutla has long suffered from asthma and during the product's creation Shetty also discovered that she suffers from asthma as a result of her poor lung function.
Coupled with the gamified app, Aluna is able to track across the spectrum of inputs that doctors need to provide the best possible care.
Aluna is an award-winning at-home spirometer and app that offer asthma, COPD and cystic fibrosis patients and doctors control and confidence in preventing attacks before they happen.
Aluna's system gamifies spirometry, encourages proper technique, and rewards patients for taking daily readings.
Aluna has been awarded by the National Science Foundation for the development of its respiratory management tool.
Matrix works with product people from day one to help them win. We're a team of builders who lead pre-seed through series A rounds.
Recent investments include Afterpay, Apartment List, Canva, Courier, CTRL-Labs, Fivetran, Flock Safety, GOAT, HubSpot, LogRocket, Markforged, Oculus, Side, Steadily, and Zendesk.
Founded in 1977, we have been at this for a while: from FedEx and Apple through 65+ IPOs, the firm has seen it all.
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment
Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine
Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant